Quantcast

Industry news that matters to you.  Learn more

Banyan Biomarkers Reports Successful Clinical Trial Results of Blood Test to Evaluate Mild and Moderate Traumatic Brain Injury

Banyan Biomarkers, Inc., the leader in developing biomarkers for traumatic brain injury (TBI), today announced the results of a clinical study utilizing a blood test to evaluate mild and moderate TBI. The results, published online in the Journal of Neurotrauma, indicate that the two highly brain specific biomarkers in Banyan Biomarkers’ blood test, ubiquitin c-terminal hydrolase-L 1 (UCH-L1) and glial fibrillary acidic protein (GFAP), are detectable in blood shortly after a TBI. The test was able to identify 100% of the trial subjects who went on to have a positive computed tomography (CT) scan of the head. The results demonstrate that early biomarker testing for patients with mild to moderate TBI has the potential to provide clinicians with objective evidence needed to reduce CT use that is associated with increased healthcare costs and developing cancer over the long term.

Study Examines Blood Biomarkers Upon Erythropoietin Treatment of Ischemic Stroke

Researchers at the Max Planck Institute of Experimental Medicine in Goettingen, Germany, led by Prof. Hannelore Ehrenreich, the University of Bremen and University of Hannover, in collaboration with Dr. Andreas Jeromin at Banyan Biomarkers, Inc, in Alachua, FL, have identified a panel of protein-based blood biomarkers in patients treated with erythropoietin (EPO), which correlate with positive outcome in this study.